These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20580245)

  • 1. Long-term survival of 42 patients with resected N2 non-small-cell lung cancer: the impact of 2-(18)F-fluoro-2-deoxy-D-glucose positron emission tomogram mediastinal staging.
    Barnett S; Baste JM; Murugappan K; Tog C; Berlangieri S; Scott A; Seevanayagam S; Knight S
    Eur J Cardiothorac Surg; 2011 Jan; 39(1):96-101. PubMed ID: 20580245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
    J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.
    Gómez-Caro A; Garcia S; Reguart N; Arguis P; Sanchez M; Gimferrer JM; Marrades R; Lomeña F
    Eur J Cardiothorac Surg; 2010 May; 37(5):1168-74. PubMed ID: 20116273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
    Gómez-Caro A; Boada M; Cabañas M; Sanchez M; Arguis P; Lomeña F; Ramirez J; Molins L
    Eur J Cardiothorac Surg; 2012 Jul; 42(1):93-100; discussion 100. PubMed ID: 22290911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.
    Al-Sarraf N; Aziz R; Gately K; Lucey J; Wilson L; McGovern E; Young V
    Eur J Cardiothorac Surg; 2008 Jan; 33(1):104-9. PubMed ID: 17977738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma.
    Raz DJ; Odisho AY; Franc BL; Jablons DM
    J Thorac Cardiovasc Surg; 2006 Nov; 132(5):1189-95. PubMed ID: 17059942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. False-positivity of mediastinal lymph nodes has negative effect on survival in potentially resectable non-small cell lung cancer.
    Iskender I; Kadioglu SZ; Cosgun T; Kapicibasi HO; Sagiroglu G; Kosar A; Kir A
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):874-9. PubMed ID: 22423060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3.
    Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer.
    Ose N; Sawabata N; Minami M; Inoue M; Shintani Y; Kadota Y; Okumura M
    Eur J Cardiothorac Surg; 2012 Jul; 42(1):89-92. PubMed ID: 22290887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.
    Trister AD; Pryma DA; Xanthopoulos E; Kucharczuk J; Sterman D; Rengan R
    Am J Clin Oncol; 2014 Apr; 37(2):135-9. PubMed ID: 23111361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer.
    Perigaud C; Bridji B; Roussel JC; Sagan C; Mugniot A; Duveau D; Baron O; Despins P
    Eur J Cardiothorac Surg; 2009 Oct; 36(4):731-6. PubMed ID: 19632852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.
    Harders SW; Madsen HH; Hjorthaug K; Arveschoug AK; Rasmussen TR; Meldgaard P; Hoejbjerg JA; Pilegaard HK; Hager H; Rehling M; Rasmussen F
    Cancer Imaging; 2014 Jun; 14(1):23. PubMed ID: 25608616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.
    Ripley RT; Suzuki K; Tan KS; Adusumilli PS; Huang J; Park BJ; Downey RJ; Rizk NP; Rusch VW; Bains M; Jones DR
    J Thorac Cardiovasc Surg; 2016 Apr; 151(4):969-77, 979.e1-3. PubMed ID: 26614420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
    Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
    Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
    Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
    Park HK; Jeon K; Koh WJ; Suh GY; Kim H; Kwon OJ; Chung MP; Lee KS; Shim YM; Han J; Um SW
    Respirology; 2010 Nov; 15(8):1179-84. PubMed ID: 20573058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.